The UK’s GW Pharma has insisted there will be no repeat of the controversy seen with cystic fibrosis drugs after NICE said “no” to regular NHS funding for its Epidyolex for rare forms of ch
The use of medical cannabis in the UK has moved a step closer, after the home secretary asked for advice following a review that concluded that there is evidence of therapeutic benefit.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
